Medicus Pharma LTD 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Medicus Pharma Ltd. has filed an amendment to its 2025 Form 10-K, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.
NASDAQ
Medicus Pharma Ltd. announced positive Phase 2 clinical trial results for its D-MNA skin cancer treatment and provided updates on its Teverelix program and financing activities, despite ongoing operating losses and a going concern warning.
NASDAQ
Medicus Pharma Ltd. files an amendment to its annual report on Form 10-K to include information required by Part III, covering directors, executive officers, corporate governance, and executive compensation.
NASDAQ
Medicus Pharma Ltd. outlines the terms and conditions of its common and preferred shares, as well as outstanding public and 2030 warrants, in its recent Form 10-K filing.